Santhera Pharmaceuticals Holding AG (SANN.SW)
- Previous Close
9.50 - Open
9.53 - Bid --
- Ask --
- Day's Range
9.35 - 9.59 - 52 Week Range
6.05 - 14.62 - Volume
14,710 - Avg. Volume
24,885 - Market Cap (intraday)
110.943M - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-8.63 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
www.santhera.comRecent News: SANN.SW
Performance Overview: SANN.SW
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SANN.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SANN.SW
Valuation Measures
Market Cap
110.94M
Enterprise Value
150.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.26
Price/Book (mrq)
--
Enterprise Value/Revenue
29.21
Enterprise Value/EBITDA
-4.29
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.31%
Return on Equity (ttm)
--
Revenue (ttm)
5.16M
Net Income Avi to Common (ttm)
-64.69M
Diluted EPS (ttm)
-8.63
Balance Sheet and Cash Flow
Total Cash (mrq)
1.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.97M
Research Analysis: SANN.SW
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: SANN.SW
SANN.SW does not have Company Insights